First Quarter 2008 - Issues in Hematology - ION Solutions

More documents

Recommendations

Info

drug updateBased on recent findingswith Nexavar in patientswith HCC, the NCCN hasupdated the clinicalpractice guideline forhepatobiliary cancersto include Nexavar asa treatment option forselected patients withboth Child-Pugh A and Bliver function status. 4oncologistics volume 7, issue 1 - spring 2008 1
oncologistics drug updateNexavar ® in Unresectable HCC:New Treatment Option Basedon Significant Survival Benefitby: Ralph Boccia, M.D., F. A. C. P.Nexavar (sorafenib) is an oral multiple kinase inhibitorthat, as of November 2007, became the first systemictherapy approved by the U.S. Food and DrugAdministration (FDA) for patients with unresectablehepatocellular carcinoma (HCC), the most common formof liver cancer. As the only agent that has demonstrateda significant survival advantage in patients withunresectable HCC, Nexavar offers new hope for thisdifficult-to-treat disease. The HCC indication came within2 years of Nexavar’s approval for advanced renal cellcarcinoma (RCC)–for which the agent is now approved inmore than 60 countries.The incidence of HCC has been rising in the UnitedStates and globally. Current estimates are thatapproximately 19,000 new HCC cases are diagnosedannually in the United States. 1 The classic late diseasestage at diagnosis and the lack of effective systemictherapies have contributed to the dismal 8% 3-yearsurvival rate among patients with advanced disease. 2SHARP Results Move HCC to the Era ofTargeted TherapyFinal results of the international, double-blind, PhaseIII Sorafenib HCC Assessment Randomized Protocol(SHARP) trial, 3 which provided the basis for the FDA’sapproval of Nexavar in HCC, marked the first time anyagent has shown a survival advantage with predictableside effects in patients with unresectable HCC, and hasmoved HCC to the era of targeted therapy.The SHARP trial, reported at the 2007 annual meetingof the American Society of Clinical Oncology, enrolled602 patients recruited from centers in North and SouthAmerica, Europe, Australia, and New Zealand. 3Patients had histologically proven unresectable ormetastatic HCC, had not received previous systemictherapy, Eastern Cooperative Oncology Group(ECOG) performance status of 0-2, and lifeexpectancy of > 12 weeks. Patients could have receivedlocal therapy, including surgery, radiotherapy, hepaticarterial embolization, chemoembolization radiofrequencyablation, percutaneous ethanol injection, or cryoablation,as long as one target lesion had not been subjected tolocal therapy or a treated target lesion had increased insize by 25%. Patients were randomly assigned to receiveoral Nexavar tablets 400 mg twice daily (n=299) orplacebo tablets twice daily (n=303) dosed continuously.Primary study end points were overall survival (OS) andtime to symptom progression. Secondary end pointswere time to disease progression and disease controlrate, defined as complete or partial response or stabledisease for at least two treatment cycles.Baseline patient characteristics were similar in thetwo treatment groups. The median patient age wasapproximately 67 years, 87% were men, and 54% hadECOG performance status of 0. The majority of studyparticipants (> 95%) had Child-Pugh A liver functionstatus, approximately 82% had Barcelona Clinic LiverCancer (BCLC) stage C disease, and 70% had portalvein thrombosis.In February 2007, when 321 deaths had occurred(143 in the Nexavar arm, 178 in the placebo arm), thestudy was terminated early, after a prescheduled interimanalysis showed that the primary OS end pointoncologistics 2
Page 2 and 3: C O M I N G S O O NfromCEPHALON ONC
Page 4 and 5: © 2007 Bristol-Myers Squibb Compan
Page 6 and 7: industry insightHOSPIRA’S INCREAS
Page 8 and 9: industry insightWhat core competenc
Page 10 and 11: industry insightWhat differentiates
Page 12 and 13: XELODAEfficacy that makes a differe
Page 14 and 15: Brief summary of prescribing inform
Page 16 and 17: oncologistics volume 7, issue 1 - s
Page 20 and 21: IV IRON SUPPORTTHROUGHOUT CHEMOTHER
Page 22 and 23: established, and the test dose has
Page 24 and 25: eimbursement watchoncologistics vol
Page 26 and 27: eimbursement watch14236132158151241
Page 28 and 29: eimbursement watchon a coverage top
Page 30 and 31: drug updateTHESE STUDIESDEMONSTRATE
Page 32 and 33: drug updateoncologistics volume 7,
Page 34 and 35: POWER ANDPERFORMANCEVIDAZA hits MDS
Page 38 and 39: drug updatehad been met. Median OS
Page 40 and 41: drug update(PDGF-ß), FLT-3, RET, a
Page 42 and 43: FURTHER PROGRESS IN THE TREATMENT O
Page 46 and 47: nurse’s forumOUTPATIENT MANAGEMEN
Page 48 and 49: nurse’s forumoncologistics volume
Page 50 and 51: oncologistics eye on ionEYE on IONG
Page 52 and 53: Note for printer: NOVARTIS 2PG INSE
Page 55 and 56: “ ION provides me with a better v

First Quarter 2008 - Issues in Hematology - ION Solutions

Create successful ePaper yourself

Delete template?

Save as template?